Free Trial
NASDAQ:CTXR

Citius Pharmaceuticals Q1 2025 Earnings Report

Citius Pharmaceuticals logo
$0.72 -0.09 (-11.23%)
Closing price 05/6/2025 03:57 PM Eastern
Extended Trading
$0.74 +0.02 (+2.23%)
As of 05/6/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citius Pharmaceuticals EPS Results

Actual EPS
-$1.30
Consensus EPS
-$1.25
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Citius Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Citius Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Friday, February 14, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Citius Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Monday, May 12, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Citius Pharmaceuticals Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Citius Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Pharmaceuticals and other key companies, straight to your email.

About Citius Pharmaceuticals

Citius Pharmaceuticals (NASDAQ:CTXR), a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

View Citius Pharmaceuticals Profile

More Earnings Resources from MarketBeat